GeoVax Labs Inc. Common Stock
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.
GOVX Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$0.5700 |
Previous Close Volume |
165960 |
Latest News
- GeoVax to Present at the 36th Annual Roth Conference 12 Mar 2024 09:10:43
- GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System 06 Mar 2024 09:10:34
- GeoVax Reports 2023 Year-End Financial Results and Provides Business Update 29 Feb 2024 16:10:37
- GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 22 Feb 2024 09:10:33
- GeoVax to Present at the 2024 BIO CEO & Investor Conference 19 Feb 2024 09:10:48
- GeoVax Announces Multiple Patent Issuances and Allowances 13 Feb 2024 09:10:25
- GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster 06 Feb 2024 09:10:35
- GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement 29 Jan 2024 09:10:30
- GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 27 Dec 2023 14:45:17
- GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress 30 Nov 2023 17:15:17
- GeoVax to Participate in Upcoming December Investor Events 29 Nov 2023 09:30:14
- GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress 28 Nov 2023 09:15:16
- Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 14 Nov 2023 09:15:14
- GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update 08 Nov 2023 16:16:59
- GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 31 Oct 2023 09:15:14
- GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine 30 Oct 2023 18:00:13
- GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 26 Jul 2023 09:10:25
- GeoVax Announces Issuance of Ebola Vaccine Patent 24 Jul 2023 09:30:45